Analgesic effects of Ephedra herb and ephedrine alkaloids-free Ephedra herb extract (EFE)

2022 ◽  
pp. 385-400
Author(s):  
Sumiko Hyuga ◽  
Shunsuke Nakamori ◽  
Yoshiaki Amakura ◽  
Masashi Hyuga ◽  
Nahoko Uchiyama ◽  
...  
2019 ◽  
Vol 42 (9) ◽  
pp. 1538-1544 ◽  
Author(s):  
Shunsuke Nakamori ◽  
Jun Takahashi ◽  
Sumiko Hyuga ◽  
Jinwei Yang ◽  
Hiroaki Takemoto ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Hiroshi Odaguchi ◽  
Mariko Sekine ◽  
Sumiko Hyuga ◽  
Toshihiko Hanawa ◽  
Keika Hoshi ◽  
...  

Ephedra Herb is an important crude drug; it is used in various Traditional Japanese Medicine (Kampo) formulations. Its significant pharmacological effects have been believed to be attributed to ephedrine and pseudoephedrine, which sometimes induce adverse effects. On the other hand, it has been reported that some of these pharmacological effects are not dependent on ephedrine or pseudoephedrine. Ephedrine alkaloids-free Ephedra Herb extract has been newly developed. It has been reported to have analgesic, anti-influenza, and antimetastatic effects. This clinical trial was aimed at verifying the noninferiority of EFE’s safety compared to that of Ephedra Herb extract (EHE) in humans. This was a single-institution, double-blinded, randomized, two-drug, two-stage, crossover comparative study. Twelve healthy male subjects were equally and randomly allocated into two groups: prior administration of EFE (EFE-P) and prior administration of EHE (EHE-P). In Stage 1, EFE and EHE were orally administered to the EFE-P and EHE-P groups, respectively, for six days. After a 4-week washout period, Stage 2 was initiated wherein the subjects were given a study drug different from Stage 1 study drug for six days. Eleven adverse events with a causal relationship to the study drugs (EHE: 8; EFE: 3) were noted; all events were mild in severity. With regard to the incidence of adverse events, EHE and EFE administration, respectively, accounted for 4 cases (out of 12 subjects, similarly below) and 1 case of increased pulse rate (p=0.32) and 3 cases and 1 case of insomnia (p=0.59). Further, there was one case of hot flashes (p=1.00) due to EFE administration and one case of dysuria (p=1.00) due to EHE administration. There were no significant differences in the incidences of adverse events between EHE administration and EFE administration. Therefore, we concluded that EFE is not inferior to EHE in terms of safety.


2020 ◽  
Vol 68 (2) ◽  
pp. 140-149 ◽  
Author(s):  
Morio Yoshimura ◽  
Yoshiaki Amakura ◽  
Sumiko Hyuga ◽  
Masashi Hyuga ◽  
Shunsuke Nakamori ◽  
...  

2017 ◽  
Vol 72 (1) ◽  
pp. 73-79 ◽  
Author(s):  
Naohiro Oshima ◽  
Takuro Maruyama ◽  
Tadatoshi Yamashita ◽  
Nahoko Uchiyama ◽  
Yoshiaki Amakura ◽  
...  

2018 ◽  
Vol 41 (2) ◽  
pp. 247-253 ◽  
Author(s):  
Hiroaki Takemoto ◽  
Jun Takahashi ◽  
Sumiko Hyuga ◽  
Hiroshi Odaguchi ◽  
Nahoko Uchiyama ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document